Key result
ME/CFS shows no difference in blood T-cell receptor diversity versus healthy controls or MS.
Why the study?
Myalgic Encephalomyelitis lacks laboratory tests and clear aetiology, but its onset after infection suggested it might be an autoimmune disease or stem from abnormal T-cell activation.
Does T-cell receptor diversity differ between people with Myalgic Encephalomyelitis and healthy or disease controls?
Case-Control (n=160)
Blinded for analysis
No
Does T-cell receptor diversity differ between people with Myalgic Encephalomyelitis and healthy or disease controls?
p-value: p=>0.05
T-cell receptor diversity in peripheral blood does not significantly differ between patients with ME/CFS and controls, challenging the hypothesis of widespread abnormal T-cell clonal expansion in this disease.
TCR diversity testing lacks diagnostic value in ME/CFS; leaves open whether localized or functional T-cell changes contribute to pathogenesis.
Objective: Myalgic Encephalomyelitis (ME; sometimes referred to as Chronic Fatigue Syndrome or CFS) is a chronic disease without laboratory test, detailed aetiological understanding or effective therapy. Its symptoms are diverse, but it is distinguished from other fatiguing illnesses by the experience of post-exertional malaise, the worsening of symptoms even after minor physical or mental exertion. Its frequent onset after infection might indicate that it is an autoimmune disease or that it arises from abnormal T-cell activation. Results: To test this hypothesis, we sequenced the genomic loci of a/d, b and g T-cell receptors (TCR) from 40 human blood samples from each of four groups: severely affected people with ME/CFS; mildly or moderately affected people with ME/CFS; people diagnosed with Multiple Sclerosis, as disease controls; and, healthy controls. Seeking to automatically classify these individuals’ samples by their TCR repertoires, we applied P-SVM, a machine learning method. However, despite working well on a simulated data set, this approach did not partition samples into the four subgroups, beyond what was expected by chance alone. Our findings do not support the hypothesis that blood samples from people with ME/CFS frequently contain altered T-cell receptor diversity.
No takes yet. Share an insight, caveat, or question.
Dibble et al. (2023) conducted a case-control in Myalgic Encephalomyelitis (ME/CFS) (n=160). T-cell receptor (TCR) sequencing vs. Healthy controls and Multiple Sclerosis patients was evaluated on Difference in T-cell clonotype expansion/diversity (p=>0.05). T-cell receptor diversity in blood samples from people with ME/CFS did not significantly differ from that of healthy controls or people with multiple sclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: